NASDAQ:VCNX Vaccinex Q1 2024 Earnings Results & Report $0.70 0.00 (0.00%) As of 10/20/2026 02:14 PM Eastern Vaccinex reported Q1 2024 earnings on May 15, 2024. The company reported EPS of -$2.94, while revenue was $0.10 million. Research:Profile Earnings Announcement Details QuarterQ1 2024Report DateMay 15, 2024 Vaccinex EPS ResultsActual EPS-$2.94Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AVaccinex Revenue ResultsActual Revenue$0.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVaccinex's next earnings date is estimated for Monday, November 16, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Vaccinex Q1 2024 Earnings FAQ Did Vaccinex beat earnings estimates for Q1 2024? Vaccinex (NASDAQ:VCNX) reported earnings of -$2.94 per share for Q1 2024. The report was announced on Wednesday, May 15, 2024. What was Vaccinex's revenue for Q1 2024? Vaccinex reported revenue of $0.10 million for Q1 2024. When is Vaccinex's next earnings date? Vaccinex's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vaccinex on the company's earnings history page. Vaccinex Earnings HeadlinesSEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma StudyOctober 7, 2026 | globenewswire.comVaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026July 8, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 21 at 1:00 AM | Porter & Company (Ad)Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025April 29, 2026 | quiverquant.comQVaccinex Reports 2025 Annual Financial ResultsApril 29, 2026 | globenewswire.comVaccinex Inc.April 10, 2026 | barrons.comSee More Vaccinex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaccinex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaccinex and other key companies, straight to your email. Email Address About VaccinexVaccinex (NASDAQ:VCNX) is a clinical-stage biotechnology company headquartered in Rochester, New York. The company develops antibody-based therapies for serious diseases, with a focus on conditions involving neurodegeneration, cancer and immune-system dysfunction. Vaccinex’s lead product candidate is pepinemab, also known as VX15/2503, a humanized monoclonal antibody designed to block Semaphorin 4D (SEMA4D). The company has evaluated pepinemab in clinical studies for Huntington’s disease and Alzheimer’s disease, as well as in oncology programs, including research investigating its potential use in combination with other cancer treatments. Vaccinex also maintains antibody-discovery and development capabilities intended to support the creation of additional therapeutic candidates and potential collaborations. The company’s programs are developed through clinical research conducted in the United States and in collaboration with academic and industry partners. Vaccinex was co-founded by Maurice Zauderer, Ph.D., who has served as its president and chief executive officer.View Vaccinex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX Earnings Launch: High Margins Fund AI AmbitionsSynchrony Aces The Quarter As Credit Fears FadeHigher Rates Are Sending Investors to These 3 Dividend KingsServiceNow Orchestrates AI's Next Act—Can Earnings Deliver?Swiping to Record Highs: Why Visa Remains a FortressDrone Stocks Have Burned Investors—Are These 4 Different?Steel Dynamics Eyes New Highs Despite Earnings Miss Upcoming Earnings Comcast (10/22/2026)Spotify Technology (10/22/2026)Procter & Gamble (10/22/2026)Valero Energy (10/22/2026)Barclays (10/22/2026)Blackstone (10/22/2026)Nasdaq (10/22/2026)Bloom Energy (10/22/2026)Honeywell International (10/22/2026)Lockheed Martin (10/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
